Creathor Venture and High-Tech Gründerfonds accelerate growth of SIRION BIOTECH with further investment

30-Jun-2011 - Germany

In addition to Creathor Venture the investors High-Tech-Gründerfonds, KfW, and Bayernkapital also joined the current round to further fund the young Munich based biotech. SIRION’s core competence lies in the development and marketing of adenoviral and lentiviral vector technologies in the field of target validation.

A part of the new proceeds will be used to further promote already developed technologies and services. One focus will be an internationalization strategy to generate further clients in the EU and the US-market, where SIRION already has first prominent clients such as the FDA. In addition the funds will be used to further support the development of new vector-technologies that are essential for the vaccine-industry. First patents were filed in 2010 and cover a technology that will be essential for developing new vaccines against human Cytomegalo-Virus, Human Immundeficiency-Virus or Tuberculosis.

Karlheinz Schmelig, Partner at Creathor Venture states, that the the investment was made due to the current market situation and the recent results of the internal research activities: “SIRION was able to prove both a significant market need and demand for its products and showed that it is able to develop innovative products.”

This statement is somplemented by the management-team, Drs. Jürgen Flach (CEO) and Christian Thirion (CSO): „Due to the current round we will be able to raise the significant sales potential of our pipeline projects and launch new technologies in new markets such as the vaccine-market.

Other news from the department business & finance

Most read news

More news from our other portals

Fighting cancer: latest developments and advances